Gw Research Limited

Otsuka Pharmaceutical Company, Limited

Gw Pharma Limited

Jazz Pharmaceuticals Research UK Limited

Daniela Parolaro

Geoffrey W Guy

Stephen Wright

Marie Woolley-Roberts

James Brodie

Rafael Maldonado

Livio Luongo

Tetsuro Kikuchi

Colin Stott

Vincenzo Di Marzo

Luciano De Petrocellis

Alan Sutton

Angelo Antonio Izzo

Etienne De Meijer

Sofia Torres

Mar Lorente

Alessia Ligresti

David Potter

Guillermo Velasco

Manuel Guzman

Sharon Anavi-Goffer

Lesley Ann Ford

Ruth Alexandra Ross

Aniello Schiano Moriello

Gabriella Aviello

Paola Massi

Brian Anthony Whittle

Francesca Borrelli

Francesca Borelli

Joanna Neill

Harpreet Singh

The present invention relates to the use of cannabidiolic acid (CBDA) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders, such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). CBDA has been shown to be particularly effective in improving cognitive dysfunction in rodent models of ASD, FXS, RS and AS. The CBDA is preferably substantially pure. It may take the form of a highly purified extract ofsuch that the CBDA is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBDA is synthetically produced.

Use of cannabidiolic acid in the treatment of autism spectrum disorder and associated disorders

The present invention relates to the use of cannabidivarin (CBDV) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). In a further embodiment the invention relates to the use of CBDV in the treatment of schizophrenia. CBDV has been shown to be particularly effective in improving cognitive dysfunction in rodent models of ASD, FXS, RS, AS and schizophrenia. The CBDV is preferably substantially pure. It may take the form of a highly purified extract ofsuch that the CBDV is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBDV is synthetically produced.

Use of cannabidivarin in the treatment of autism spectrum disorder, associated disorders and schizophrenia

This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.

Phytocannabinoids in the treatment of cancer

Growing community of inventors

Varese, Italy

Daniela Parolaro